Cover Image
市場調查報告書

MediPoint:主動脈覆膜支架 - 歐盟市場分析與預測

MediPoint: Aortic Stent Grafts - EU Analysis and Market Forecasts

出版商 GlobalData 商品編碼 319561
出版日期 內容資訊 英文 208 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:主動脈覆膜支架 - 歐盟市場分析與預測 MediPoint: Aortic Stent Grafts - EU Analysis and Market Forecasts
出版日期: 2014年10月31日 內容資訊: 英文 208 Pages
簡介

主動脈覆膜支架,是為了加強稱為動脈瘤的動脈薄弱的部位,最常使用的裝置。血管支架,置入患者的動脈,設計成能在動脈瘤的上下好好地封住。不僅僅是腹部主動脈血管瘤,也用於胸部主動脈瘤的治療。

本報告提供EU5個國家(法國、德國、義大利、西班牙、英國)的主動脈覆膜支架設備市場相關調查分析、產業概要、未滿足需求、市場機會、推動市場要素、競爭評估、開發中產品驗證、主要企業簡介等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 概要
  • 適應症
  • 臨床結果
  • 治療趨勢
  • 市場進入
  • 法規問題/回收
  • 合併、交易、收購
  • 經濟影響

第4章 未滿足需求

  • 併發症應對
  • 封閉處和定位區
  • Short Neck
  • 費用的抑制
  • 不突出的系統
  • 專用的有孔血管支架
  • 分歧型血管支架
  • 胸部血管內動脈瘤修復:未滿足需求
  • 長期性的臨床資料

第5章 市場機會分析

  • 胸部主動脈疾病市場
  • 追加醫生的訓練計劃
  • 創新的技術
  • 微創趨勢

第6章 推動市場要素、障礙、替代

  • 推動因素
  • 障礙
  • 替代

第7章 競爭評估

  • 概要
  • 主要上市產品

第8章 開發平台評估

  • 概要
  • 產品簡介

第9章 值得注意的臨床試驗

第10章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Cook Medical
    • Endologix
    • Gore Medical
    • Medtronic
    • Terumo Corporation
    • Altura Medical
    • Aptus Endosystems
    • Bolton Medical
    • Braile Biomedica
    • B. Braun
    • Cardiatis
    • LeMaitre Vascular
    • Lifetech Scientific
    • Getinge Group
    • Grikin Advanced Materials
    • Johnson & Johnson's Cordis Corporation
    • Jotec
    • Lombard Medical
    • MicroPort Scientific Corporation
    • Nano Endoluminal
    • TriVascular
    • Weike Medical Apparatus and Instrument
    • YTH Biological Material Scitech

第11章 市場預測

  • 企業的市場佔有率
  • 各市場部門
  • 各地區

第12章 附錄

圖表

目錄
Product Code: GDME1117CFR

Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. Since their introduction in patients in 1991, aortic stent graft devices have gained wide acceptance and availability, with their adoption fueled in great part by advances in stent-graft design and by a variety of devices for various anatomic features. Over time, these devices have gained traction for use in patients with ruptured aneurysms because they are minimally invasive and have shorter recovery times.

The EU market continues to be the second biggest market for aortic stent grafts at 23% of the global scene. Of this, Germany remains the leader as they are the pioneers of cardiovascular innovations and have a strong local manufacturing base. Similar to the US, the leading companies in the EU aortic stent grafts market are Medtronic, Cook Medical, and Gore Medical, with emerging players such as Endologix.

Scope

  • An overview of Aortic Stent Grafts, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the 5EU Aortic Stent Grafts market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Aortic Stent Grafts.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Aortic Stent Grafts sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the 5EU Aortic Stent Grafts market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the 5EU Aortic Stent Grafts market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the 5EU Aortic Stent Grafts market landscape Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Industry Overview

  • 3.1. Overview
  • 3.2. Indications
    • 3.2.1. Aortic Abdominal Aneurysm
    • 3.2.2. Thoracic Aortic Aneurysm
    • 3.2.3. Aortic Dissection
  • 3.3. Clinical Outcomes
    • 3.3.1. Lifestyle Changes
    • 3.3.2. Medication
    • 3.3.3. Open Surgery
    • 3.3.4. Endovascular Repair
  • 3.4. Procedure Trends
    • 3.4.1. EU
  • 3.5. Market Access
    • 3.5.1. Adoption
    • 3.5.2. Regulation
    • 3.5.3. Reimbursement
  • 3.6. Regulatory Issues/Recalls
    • 3.6.1. Anaconda Back on the Market in March 2014 after a Voluntary Recall of Anaconda by Vascutek
    • 3.6.2. Terminated FDA's Class II Recall of TriVascular's Ovation Prime in April 2014
  • 3.7. Mergers, Deals, and Acquisitions
    • 3.7.1. Medtronic Acquires Covidien
    • 3.7.2. TriVascular Launches $100m Initial Public Offering
    • 3.7.3. Lombard Medical Pursues US Initial Public Offering
    • 3.7.4. TriVascular Raises $40m in Series E Financing
    • 3.7.5. LifeTech Scientific Creates Partnership with Medtronic
    • 3.7.6. LeMaitre Vascular Terminates Distribution Agreement with Endologix
    • 3.7.7. Jotec Enters Licensing Agreement with Hydromer
    • 3.7.8. Endologix Public Offering of Notes
    • 3.7.9. Aptus Endosystems Secures Financing
    • 3.7.10. Altura Medical Secures Financing
    • 3.7.11. Endologix Acquires Nellix Endovascular
  • 3.8. Economic Impact
    • 3.8.1. Economic Impact of Aneurysms
    • 3.8.2. Treatment Costs of Aortic Aneurysms

4. Unmet Needs

  • 4.1. Addressing the Complications
    • 4.1.1. Endoleaks
    • 4.1.2. Ischemic Complications
    • 4.1.3. Limb Thrombosis
    • 4.1.4. Infection
    • 4.1.5. Paraplegia in Thoracic Aortic Aneurysm
  • 4.2. The Seal and Landing Zone
  • 4.3. Short Neck
  • 4.4. Cost Containment
  • 4.5. More Low Profile Systems
  • 4.6. Customized Fenestrated Stent Grafts
  • 4.7. Multi-Branch Stent Grafts
  • 4.8. Thoracic Endovascular Aneurysm Repair Unmet Needs
  • 4.9. Long-Term Clinical Data

5. Market Opportunity Analysis

  • 5.1. Emerging Markets
  • 5.2. Thoracic Aortic Disease Market
  • 5.3. Addition of Physician Training Programs
  • 5.4. Disruptive Technologies
  • 5.5. Minimally Invasive Trend

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Driver: Rising Disease Prevalence
    • 6.1.1. Diabetes Mellitus
    • 6.1.2. Hypertension
    • 6.1.3. Obesity
    • 6.1.4. Tobacco Use
  • 6.2. Driver: Aging
  • 6.3. Driver: Imaging
  • 6.4. Driver: Improved Clinical Outcomes with Endovascular Therapy
  • 6.5. Driver: Time Savings
  • 6.6. Driver: Patient Demand and Awareness
  • 6.7. Driver: Technological Developments
    • 6.7.1. Custom Branched and Fenestrated Stent Grafts
    • 6.7.2. Low Profile Delivery Systems
  • 6.8. Driver: Rising Competition and Innovation
  • 6.9. Barrier: Availability of Venture Capital
  • 6.10. Barrier: Burden of Rising Regulation
  • 6.11. Barrier: High Treatment Cost
  • 6.12. Barrier: Proving Long-Term Efficacy
  • 6.13. Barrier: High Radiation Dosages with Excessive Imaging
  • 6.14. Surgical Limitations
  • 6.15. Barrier: Medical Device Excise Tax
  • 6.16. Substitute: Open Surgery
  • 6.17. Substitute: Chimney Technique versus Fenestrated Grafts

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Key Marketed Products
    • 7.2.1. Endovascular Aneurysm Repair and Thoracic Endovascular Aneurysm Repair Products

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Product Profiles
    • 8.2.1. Altura Medical Endograft
    • 8.2.2. Cordis INCRAFT
    • 8.2.3. EndoSpan Horizon
    • 8.2.4. EndoSpan Nexus
    • 8.2.5. MicroPort Scientific Castor Branched Stent Graft System
    • 8.2.6. BiFlow Medical Novel Side-Branch Stent
    • 8.2.7. Endoluminal Sciences Endograft Mechanism
    • 8.2.8. Medtronic Valiant Mona LSA Stent Graft System
    • 8.2.9. Endologix Ventana Fenestrated Stent Graft

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Altura Medical
  • 9.3. Cook Medical
  • 9.4. Gore Medical
  • 9.5. Terumo Corporation
  • 9.6. Endologix
  • 9.7. TriVascular
  • 9.8. Bolton Medical
  • 9.9. Medtronic
  • 9.10. Cordis Corporation

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Cook Medical
    • 10.3.2. Endologix
    • 10.3.3. Gore Medical
    • 10.3.4. Medtronic
    • 10.3.5. Terumo Corporation
    • 10.3.6. Altura Medical
    • 10.3.7. Aptus Endosystems
    • 10.3.8. Bolton Medical
    • 10.3.9. Braile Biomedica
    • 10.3.10. B. Braun
    • 10.3.11. Cardiatis
    • 10.3.12. LeMaitre Vascular
    • 10.3.13. Lifetech Scientific
    • 10.3.14. Getinge Group
    • 10.3.15. Grikin Advanced Materials
    • 10.3.16. Johnson & Johnson's Cordis Corporation
    • 10.3.17. Jotec
    • 10.3.18. Lombard Medical
    • 10.3.19. MicroPort Scientific Corporation
    • 10.3.20. Nano Endoluminal
    • 10.3.21. TriVascular
    • 10.3.22. Weike Medical Apparatus and Instrument
    • 10.3.23. YTH Biological Material Scitech

11. Market Outlook

  • 11.1. Company Market Share
  • 11.2. By Market Segment
    • 11.2.1. Overview
    • 11.2.2. Endovascular Aneurysm Repair
    • 11.2.3. Thoracic Endovascular Aneurysm Repair
  • 11.3. By Geography
    • 11.3.1. EU Overview
    • 11.3.2. EU

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Research Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in this Study
    • 12.4.1. Christopher Abularrage, MD, FACS
    • 12.4.2. Gaspar Mestres Alomar, MD
    • 12.4.3. Enio Buffolo, MD, PhD
    • 12.4.4. Ludovic Canaud, MD, PhD
    • 12.4.5. Holger Eggebrecht, MD
    • 12.4.6. Daisuke Fukui, MD, PhD
    • 12.4.7. Germano Melissano, MD
    • 12.4.8. Dr. Raghuram Sekhar MS, FRCS (Edinburgh), FRCS (Glasgow)
    • 12.4.9. Ferdinand Serracino-Inglott, MD, MSc, FRCSI, FRCS (Gen Surg), DIC
    • 12.4.10. Jiang Xiong, MD, PhD
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research - Physician and Industry Interviews
    • 12.5.3. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: Summary of Indications, Symptoms, and Treatments
  • Table 2: Thoracic Aortic Aneurysm Types
  • Table 3: Medications for Reducing Risk of Aneurysm Growth and Rupture
  • Table 4: Advantages and Disadvantages of Open Repair versus Endovascular Repair
  • Table 5: Group Purchasing Organizations in the EU
  • Table 6: Regulatory Differences between the US and EU
  • Table 7: Direct and Indirect Costs of Open Surgery and Endovascular Repair
  • Table 8: Comparison Costs and Other Variables for Treating AAA By Open Repair and Stent Grafts in 2012 ($US)
  • Table 9: Endoleak Types
  • Table 10: Zenith Family Marketed Products
  • Table 11: Zenith AAA SWOT
  • Table 12: Zenith TAA SWOT
  • Table 13: Endologix's Marketed Products
  • Table 14: AFX Endovascular SWOT
  • Table 15: IntuiTrak Powerlink System SWOT
  • Table 16: Gore Medical's Marketed Products
  • Table 17: Gore AAA Product SWOT
  • Table 18: Gore TAA Product SWOT
  • Table 19: Medtronic's Marketed Products
  • Table 20: Medtronic AAA Product SWOT
  • Table 21: Medtronic TAA Product SWOT
  • Table 22: Terumo Corporation Marketed Products
  • Table 23: Terumo Corporation AAA Product SWOT
  • Table 24: SWOT Analysis - Altura Medical Endograft
  • Table 25: SWOT Analysis - Cordis INCRAFT
  • Table 26: SWOT Analysis - EndoSpan Horizon
  • Table 27: SWOT Analysis - EndoSpan Nexus
  • Table 28: SWOT Analysis - MicroPort Scientific Castor Branched Stent Graft System
  • Table 29: SWOT Analysis - BiFlow Medical Novel Side-Branch Stent
  • Table 30: SWOT Analysis - Endoluminal Sciences Endograft Mechanism
  • Table 31: SWOT Analysis - Medtronic Valiant Mona LSA Stent Graft
  • Table 32: SWOT Analysis - Endologix Ventana Fenestrated Stent Graft
  • Table 33: Major Clinical Trials of Altura Medical's Aortic Stent Grafts
  • Table 34: Major Clinical Trials of Cook Medical's Aortic Stent Grafts
  • Table 35: Major Clinical Trials of Gore Medical's Aortic Stent Grafts
  • Table 36: Major Clinical Trials of Terumo's Aortic Stent Grafts
  • Table 37: Major Clinical Trials of Endologix's Aortic Stent Grafts
  • Table 38: Major Clinical Trials of TriVascular's Aortic Stent Grafts
  • Table 39: Major Clinical Trials of Bolton Medical's Aortic Stent Grafts
  • Table 40: Major Clinical Trials of Medtronic's Aortic Stent Grafts
  • Table 41: Major Clinical Trials of Cordis' Aortic Stent Grafts
  • Table 42: Company Profile - Cook Medical
  • Table 43: Cook Medical Marketed Products
  • Table 44: SWOT Analysis - Cook Medical
  • Table 45: Company Profile - Endologix Inc.
  • Table 46: Endologix Marketed Products
  • Table 47: Endologix Pipeline Products
  • Table 48: SWOT Analysis - Endologix Inc.
  • Table 49: Company Profile - Gore Medical
  • Table 50: Gore Medical Marketed Products
  • Table 51: SWOT Analysis - Gore Medical
  • Table 52: Company Profile - Medtronic
  • Table 53: Medtronic Marketed Products
  • Table 54: SWOT Analysis - Medtronic
  • Table 55: Company Profile - Terumo Corporation
  • Table 56:Terumo Corporation Marketed Products
  • Table 57: SWOT Analysis - Terumo Corporation
  • Table 58: Company Profile - Altura Medical Inc.
  • Table 59: Altura Medical Inc. Marketed Products
  • Table 60: SWOT Analysis - Altura Medical Inc.
  • Table 61: Company Profile - Aptus Endosystems, Inc.
  • Table 62: Aptus Endosystems Inc. Marketed Products
  • Table 63: SWOT Analysis - Aptus Endosystems Inc.
  • Table 64: Company Profile - Bolton Medical
  • Table 65: Bolton Medical Marketed Products
  • Table 66: SWOT Analysis - Bolton Medical
  • Table 67: Company Profile - Braile Biomedica
  • Table 68: Braile Biomedica Marketed Products
  • Table 69: SWOT Analysis - Braile Biomedica
  • Table 70: Company Profile - B. Braun
  • Table 71: B. Braun Marketed Products
  • Table 72: SWOT Analysis - B. Braun
  • Table 73: Company Profile - Cardiatis
  • Table 74: Cardiatis Marketed Products
  • Table 75: SWOT Analysis - Cardiatis
  • Table 76: Company Profile - LeMaitre Vascular
  • Table 77: LeMaitre Vascular Medical Marketed Products
  • Table 78: SWOT Analysis - LeMaitre Vascular
  • Table 79: Company Profile - Lifetech Scientific
  • Table 80: Lifetech Scientific Marketed Products
  • Table 81: SWOT Analysis - Lifetech Scientific
  • Table 82: Company Profile - Getinge Group
  • Table 83: Getinge Group Marketed Products
  • Table 84: SWOT Analysis - Getinge Group
  • Table 85: Company Profile - Grikin Advanced Materials
  • Table 86: Grikin Advanced Materials Marketed Products
  • Table 87: SWOT Analysis - Grikin Advanced Materials
  • Table 88: Company Profile - Johnson & Johnson Cordis Corporation
  • Table 89: Cordis Corporation's Pipeline Product
  • Table 90: SWOT Analysis - Cordis Corporation
  • Table 91: Company Profile - Jotec
  • Table 92: Jotec's Marketed Products
  • Table 93: SWOT Analysis - Jotec
  • Table 94: Company Profile - Lombard Medical
  • Table 95: Lombard Medical Marketed Products
  • Table 96: SWOT Analysis - Lombard Medical
  • Table 97: Company Profile - Microport Scientific Corporation
  • Table 98: MicroPort Scientific Marketed Products
  • Table 99: SWOT Analysis - MicroPort Scientific
  • Table 100: Company Profile - Nano Endoluminal
  • Table 101: Nano Endoluminal Medical Marketed Products
  • Table 102: SWOT Analysis - Nano Endoluminal
  • Table 103: Company Profile - TriVascular
  • Table 104: TriVascular Marketed Products
  • Table 105: SWOT Analysis - TriVascular
  • Table 106: 5EU Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011-2020
  • Table 107: 5EU Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Table 108: 5EU Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Table 109: Aortic Stent Grafts Sales ($m) for the 5EU, 2011-2020
  • Table 110: Aortic Stent Grafts Sales ($m) Forecast for the 5EU, 2011-2020
  • Table 111: Aortic Stent Grafts Sales ($m) Forecast for France, 2011-2020
  • Table 112: Aortic Stent Grafts Sales ($m) Forecast for Germany, 2011-2020
  • Table 113: Aortic Stent Grafts Sales ($m) Forecast for Italy, 2011-2020
  • Table 114: Aortic Stent Grafts ($m) Forecast for Spain, 2011-2020
  • Table 115: Aortic Stent Grafts Sales ($m) Forecast for the UK, 2011-2020

List of Figures

  • Figure 1: Treatment Methodology Markov Model
  • Figure 2: Aortic Stent Graft Product Image
  • Figure 3: EU Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 4: EU Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 5: EU Market Share for EVAR, 2013
  • Figure 6: EU Market Share for TEVAR, 2013
  • Figure 7: 5EU Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011-2020
  • Figure 8: 5EU Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Figure 9: 5EU Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Figure 10: Aortic Stent Grafts Sales ($m) for 5EU, 2011-2020
  • Figure 11: Aortic Stent Grafts by Major Market, 2013 and 2020
  • Figure 12: 5EU Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 13: France Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 14: Germany Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 15: Italy Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 16: Spain Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 17: UK Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 18: Aortic Stent Graft Primary Research, Supply and Demand-Side Interviews
Back to Top